Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.47 |
| ▸ | ATR | Q13535 | 3/20 | 0.37 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27194820 | 0.86 | NLRP3 (0.49) | NLRP3NAMPTJAK2ROCK2ROCK1 | |
| Water SCHEMBL30837701 | 0.85 | NLRP3 (0.48) | NLRP3NAMPTJAK2ROCK2ROCK1 | |
| SCHEMBL23037689 | 0.83 | BCHE (0.41) | BCHEGRM2NQO2BRD4AAK1 | |
| Water SCHEMBL23037698 | 0.81 | NLRP3 (0.43) | NLRP3NAMPTJAK2 | |
| SCHEMBL27194819 | 0.81 | NLRP3 (0.42) | NLRP3NAMPT | |
| SCHEMBL29325612 | 0.80 | NLRP3 (0.51) | NLRP3NAMPTJAK2ROCK2ROCK1 | |
| SCHEMBL29325634 | 0.80 | NLRP3 (0.41) | NLRP3NAMPTROCK2ROCK1 | |
| SCHEMBL23037625 | 0.80 | NLRP3 (0.49) | NLRP3ATRATRIPGRM2ROCK2 | |
| SCHEMBL29317951 | 0.80 | NLRP3 (0.51) | NLRP3JAK2 | |
| SCHEMBL29315928 | 0.80 | NLRP3 (0.56) | NLRP3NAMPTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4353235-A2 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-112521387-B | NLRP3 modulators | 先天肿瘤免疫公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-112521387-A | NLRP3 modulators | 先天肿瘤免疫公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3784670-A1 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112074516-A | NLRP3 modulators | 先天肿瘤免疫公司 | 2020-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | NLRP3 1/4885ATR 3043/4885ATRIP 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.